Agios Pharmaceuticals, Inc.
Cambridge
Massachusetts
United States
345 articles about Agios Pharmaceuticals, Inc.
-
Agios Reports Fourth Quarter and Full Year 2021 Financial Results
2/24/2022
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, reported business highlights and financial results for the fourth quarter and year ended Dec. 31, 2021.
-
The FDA has approved Agios Pharmaceuticals' Pyrukynd for a rare type of hemolytic anemia treatment. Continue reading the article to know more about the new drug.
-
Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency
2/17/2022
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, announced that the U.S. Food and Drug Administration has approved PYRUKYND® in the U.S. for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare, debilitating, lifelong hemolytic anemia.
-
Agios to Webcast Conference Call of Fourth Quarter and Year End 2021 Financial Results on Feb. 24, 2022
2/10/2022
Agios Pharmaceuticals, Inc. today announced the company will host a conference call and live webcast on Thursday, Feb. 24, 2022, at 8:00 a.m. ET to report its fourth quarter and year end 2021 financial results and other business highlights.
-
Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Company’s Strategic Vision in Genetically Defined Diseases
1/10/2022
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, announced its anticipated 2022 key milestones and priorities that will drive its transition to a commercial-stage genetically defined disease company and the expansion of its robust clinical and research portfolio.
-
He envisions becoming a grandparent in the industry, as opposed to the parenting role he played at Alnylam.
-
Agios to Present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022
12/22/2021
Agios Pharmaceuticals, Inc. today announced that the company is scheduled to present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 7:30 a.m. ET.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Agios Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition
12/13/2021
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO),today reported new data from the ongoing long-term extension study assessing the duration of effects of mitapivat on hemoglobin response and transfusion burden reduction in adults with pyruvate kinase (PK) deficiency who had participated in one of the pivotal studies, ACTIVATE and ACTIVATE-T, conducted in not regularly transfused and regularly transfused adults with PK deficiency, respectively.
-
Agios Presents Mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis in Non-transfusion-dependent α- and β-Thalassemia at 63rd ASH Annual Meeting and Exposition
12/13/2021
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), today reported data for the first time from the ongoing long-term extension period of the Phase 2 open-label study of mitapivat, a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase (PK) enzymes, in adults with non-transfusion dependent α- or β-thalassemia.
-
Agios Announces Data from Investigator-led Studies of Mitapivat in Adults with Sickle Cell Disease Demonstrating Improvements in Anemia, Hemolysis and Sickling Parameters at 63rd ASH Annual Meeting and Exposition
12/13/2021
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat genetically defined diseases, announced new data from investigator-led studies of mitapivat, a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase enzymes, in adults with sickle cell disease.
-
Agios Appoints Richa Poddar as Chief Commercial Officer
11/15/2021
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat genetically defined diseases, announced the appointment of Richa Poddar to the role of chief commercial officer, effective Dec. 6, 2021.
-
CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases
11/4/2021
Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced that it has expanded its partnership with Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases.
-
Agios to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 63rd ASH Annual Meeting and Exposition
11/4/2021
Agios Pharmaceuticals, Inc. announced that a broad set of clinical and translational data from its genetically defined disease programs in chronic hemolytic anemias, including pyruvate kinase deficiency, thalassemia and sickle cell disease, will be presented at the American Society of Hematology Annual Meeting & Exposition, to be held Dec. 11-14, 2021, virtually and in person in Atlanta.
-
Agios Reports Business Highlights and Third Quarter 2021 Financial Results
11/3/2021
Agios Pharmaceuticals, Inc. today reported business highlights and financial results for the third quarter ended Sept. 30, 2021.
-
Agios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021
10/21/2021
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), today announced the company will host a conference call and live webcast on Wednesday, Nov. 3, 2021, at 8:00 a.m. ET to report its third quarter 2021 financial results and other business highlights.
-
Agios To Present at September 2021 Investor Conferences
8/30/2021
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, announced that the company is scheduled to present at the following September investor conferences
-
Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency-- PDUFA Date Set for February 17, 2022 --
8/17/2021
Agios Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for mitapivat for the treatment of adults with pyruvate kinase (PK) deficiency.
-
Agios Reports Business Highlights and Second Quarter 2021 Financial Results
7/29/2021
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat genetically defined diseases, reported business highlights and financial results for the second quarter ended June 30, 2021.